Bioventus Inc. (BVS) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BVS | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | medical-devices | oncology |
| Price and returns | ||
| Last close | $14.72 | $123.96 |
| Return · 1 week | +9.12% | 0.00% |
| Return · 1 month | +4.99% | 0.00% |
| Return · 3 months | +11.43% | 0.00% |
| Return · year to date | +104.16% | +22.93% |
| Return · 1 year | +119.37% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −7.38% | −0.02% |
| 52-week high | $15.89 | $123.99 |
| 52-week low | $6.47 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.01B | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $6.85M | $149.69M |
| Employees | 950 | 234 |
| Valuation | ||
| Price to earnings · trailing | 16.75× | n/a (negative earnings) |
| Price to earnings · forward | 14.20× | n/a (negative forward earnings) |
| Price to sales | 1.53× | — |
| Price to book | 3.90× | 8.33× |
| Enterprise value to EBITDA | 14.41× | — |
| Enterprise value to revenue | 1.99× | — |
| PEG ratio | 1.53 | — |
| Earnings per share · trailing | 0.78 | -6.06 |
| Profitability | ||
| Gross margin | 68.65% | — |
| Operating margin | 12.23% | 0.00% |
| Profit margin | 9.36% | — |
| Return on equity | 25.68% | −41.19% |
| Return on assets | 5.49% | −22.51% |
| Growth | ||
| Revenue growth | +3.80% | — |
| Earnings growth | +327.30% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 95.08 | — |
| Current ratio | 1.69 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 62.08 | — |
| ADX · 14 | 18.92 | — |
| 50-day average | $13.70 | — |
| 200-day average | $10.77 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.56% | — |
The full BVS analysis
Everything this table leaves out for Bioventus Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BVS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BVS analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis